Arcutis Biotherapeutics Stock Five Year Return
| ARQT Stock | USD 13.04 1.33 11.36% |
Arcutis Biotherapeutics fundamentals help investors to digest information that contributes to Arcutis Biotherapeutics' financial success or failures. It also enables traders to predict the movement of Arcutis Stock. The fundamental analysis module provides a way to measure Arcutis Biotherapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Arcutis Biotherapeutics stock.
Arcutis | Five Year Return |
Arcutis Biotherapeutics Company Five Year Return Analysis
Arcutis Biotherapeutics' Five Year Return is considered one of the best measures to evaluate fund performance, especially from the mid and long term perspective. It shows the total annualized return generated from holding equity for the last five years and represents capital appreciation of the investment, including all dividends, losses, and capital gains distributions.
More About Five Year Return | All Equity Analysis
Five Year Return | = | (Mean of Monthly Returns - 1) | X | 100% |
Arcutis Five Year Return Driver Correlations
Understanding the fundamental principles of building solid financial models for Arcutis Biotherapeutics is extremely important. It helps to project a fair market value of Arcutis Stock properly, considering its historical fundamentals such as Five Year Return. Since Arcutis Biotherapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Arcutis Biotherapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Arcutis Biotherapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Although Five Year Returns can give a sense of overall investment potential, it is recommended to compare equity performance with similar assets for the same five year time interval. Similarly, comparing overall investment performance over the last five years with the appropriate market index is a great way to determine how this equity instrument will perform during unforeseen market fluctuations.
| Competition |
Arcutis Return On Tangible Assets
Return On Tangible Assets |
|
According to the company disclosure, Arcutis Biotherapeutics has a Five Year Return of 0.0%. This indicator is about the same for the Biotechnology average (which is currently at 0.0) sector and about the same as Health Care (which currently averages 0.0) industry. This indicator is about the same for all United States stocks average (which is currently at 0.0).
Arcutis Five Year Return Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Arcutis Biotherapeutics' direct or indirect competition against its Five Year Return to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Arcutis Biotherapeutics could also be used in its relative valuation, which is a method of valuing Arcutis Biotherapeutics by comparing valuation metrics of similar companies.Arcutis Biotherapeutics is currently under evaluation in five year return category among its peers.
Arcutis Biotherapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Arcutis Biotherapeutics from analyzing Arcutis Biotherapeutics' financial statements. These drivers represent accounts that assess Arcutis Biotherapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Arcutis Biotherapeutics' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 830.3M | 1.0B | 1.0B | 223.9M | 257.4M | 244.6M | |
| Enterprise Value | 767.3M | 943.2M | 1.0B | 341.4M | 392.6M | 373.0M |
Arcutis Biotherapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Arcutis Biotherapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Arcutis Biotherapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Arcutis Fundamentals
| Return On Equity | -1.92 | ||||
| Return On Asset | -0.31 | ||||
| Profit Margin | (1.41) % | ||||
| Operating Margin | (0.87) % | ||||
| Current Valuation | 1.4 B | ||||
| Shares Outstanding | 117.05 M | ||||
| Shares Owned By Insiders | 2.10 % | ||||
| Shares Owned By Institutions | 97.90 % | ||||
| Number Of Shares Shorted | 25.02 M | ||||
| Price To Book | 9.74 X | ||||
| Price To Sales | 11.00 X | ||||
| Revenue | 59.61 M | ||||
| Gross Profit | 2.93 M | ||||
| EBITDA | (227.43 M) | ||||
| Net Income | (262.14 M) | ||||
| Cash And Equivalents | 282.17 M | ||||
| Cash Per Share | 5.47 X | ||||
| Total Debt | 205.92 M | ||||
| Debt To Equity | 0.40 % | ||||
| Current Ratio | 10.75 X | ||||
| Book Value Per Share | 1.34 X | ||||
| Cash Flow From Operations | (247.06 M) | ||||
| Short Ratio | 11.20 X | ||||
| Earnings Per Share | (1.67) X | ||||
| Price To Earnings To Growth | (0.31) X | ||||
| Target Price | 19.0 | ||||
| Number Of Employees | 296 | ||||
| Beta | 1.19 | ||||
| Market Capitalization | 1.53 B | ||||
| Total Asset | 341.37 M | ||||
| Retained Earnings | (981.9 M) | ||||
| Working Capital | 283.76 M | ||||
| Current Asset | 87.18 M | ||||
| Current Liabilities | 4.42 M | ||||
| Net Asset | 341.37 M |
About Arcutis Biotherapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Arcutis Biotherapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Arcutis Biotherapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Arcutis Biotherapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Arcutis Stock Analysis
When running Arcutis Biotherapeutics' price analysis, check to measure Arcutis Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arcutis Biotherapeutics is operating at the current time. Most of Arcutis Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Arcutis Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arcutis Biotherapeutics' price. Additionally, you may evaluate how the addition of Arcutis Biotherapeutics to your portfolios can decrease your overall portfolio volatility.